Zoetis (ZTS) Lenivia Launch Puts Valuation Back In Focus
Lenivia launch puts Zoetis stock back on investors’ radar
Zoetis (ZTS) has just rolled out Lenivia, a long acting monoclonal antibody therapy for canine osteoarthritis pain, offering up to three months of relief from a single injection in Canada and the EU.
See our latest analysis for Zoetis.
Despite the Lenivia launch and recent vaccine approvals in Europe, Zoetis has been under pressure, with the share price at $76.91 and the year to date share price return down 38.9%, while the 1 year total shareholder return has declined 47.9%. This points to weak momentum even after a 3.2% 1 day share price gain.
If Lenivia and other new therapies have you rethinking where growth in animal and human health intersects with AI, it may be worth checking a screener focused on 39 healthcare AI stocks
The question now is whether Zoetis’ sharp share price reset reflects a shift in how the business is priced, or whether sentiment around lawsuits, guidance cuts and new launches has simply swung too far, which brings the focus to valuation.
Most Popular Narrative: 17.2% Undervalued
According to a widely followed narrative on Zoetis, the stock’s fair value sits at $92.92 compared with the last close at $76.91, putting valuation firmly in focus for investors weighing Lenivia and the recent sell off.
The company was spun off from Pfizer in 2013 as the “animal pharma” division, and makes medicines for pets and livestock. The pet division, which they call the “Companion Animal” segment, does about $6.5B in revenues, with most of it coming from dogs and cats. The livestock segment drew in about $2.7B in revenues in FY25, with about half of it coming from cattle. Think of allergies or diabetes in pets, serious illnesses which warrant pharmaceutical treatment and an expense that households are willing to spend on a “family member”. That is what Zoetis addresses in a nutshell together with its network of veterinarian clinics across the world.
The narrative backing that $92.92 fair value leans heavily on steady revenue growth, firm profit margins and a future earnings multiple that sits below many peers. It ties Zoetis’ pet heavy mix to those assumptions in a way that is very specific. But the full logic only really comes through when you see how those inputs are stitched together over time.
Result: Fair Value of $92.92 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Zoetis still faces pressure from the 11% revenue decline in its US Companion Animal segment and rising leverage from debt funded share buybacks, either of which could weaken this valuation case.
Find out about the key risks to this Zoetis narrative.
Next Steps
With Zoetis weighing both clear risks and appealing rewards, consider reviewing the full picture in 5 key rewards and 1 important warning sign without waiting for consensus to form.
Looking for more investment ideas beyond Zoetis?
If Zoetis has sharpened your focus on where to put fresh capital to work, it makes sense to scan for other stocks that fit clear, data driven criteria.
- Target value opportunities by checking companies that screen well on quality and pricing, starting with the 49 high quality undervalued stocks.
- Prioritize resilience by reviewing stocks that pair low risk profiles with solid fundamentals through the 81 resilient stocks with low risk scores.
- Spot potential early movers by scanning a screener containing 20 high quality undiscovered gems before they gain wider attention among other investors.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com